Loading
A phase 1/2 trial of ARV-806 in advanced solid tumours, run by Arvinas Inc., active and no longer recruiting.
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation is a phase 1/2 interventional study registered as NCT07023731 by Arvinas Inc., with 76 participants enrolled, started 2025-05-29 and due to reach its primary completion in 2026-11-30. Interventions recorded: ARV-806.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Arvinas, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/